Todd Berard - BioLife Solutions Vice President of Marketing
| BLFS Stock | USD 27.47 0.31 1.14% |
President
Mr. Todd Berard is the Vice President Marketing of the Company. He is responsible for corporate branding, product branding, marketing and launch strategy, and product management. He is also a key team member in the management and growth of all product launches including biologistex. Before his appointment as Vice President of Marketing, Mr. Berard had served as Senior Director of Marketing since July 2014. Previous to BioLife, Mr. Berard served as Director of Marketing at Verathon Medical a division of Roper Inc., from September 2010 until July 2014, overseeing the global marketing, product development, and product launch strategies for a portfolio of six medical device brands. He also managed all strategic partnerships for product development, and helped guide the organization. Verathon had global sales in 2014 of roughly 180M and Mr. Berard oversaw a creative and product management team of 12. Responsibilities included all global marketing initiatives and campaigns, strategy, product portfolio management, and strategic planning. He has over twenty years of experience in life sciences, health care, and technology working for both global leaders and small technology startups, including the University of Washington School of Medicine, DuPont, and Medtronic. He has a BS Degree in Biochemistry from the University of Vermont and an MBA from the University of Washington Foster School of Business. since 2015.
| Age | 55 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 3303 Monte Villa Parkway, Bothell, WA, United States, 98021 |
| Phone | 425 402 1400 |
| Web | https://www.biolifesolutions.com |
Latest Insider Transactions
Todd Berard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Todd Berard against BioLife Solutions stock is an integral part of due diligence when investing in BioLife Solutions. Todd Berard insider activity provides valuable insight into whether BioLife Solutions is net buyers or sellers over its current business cycle. Note, BioLife Solutions insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioLife Solutions'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Todd Berard over three months ago Disposition of 10000 shares by Todd Berard of BioLife Solutions at 20.18 subject to Rule 16b-3 | ||
Todd Berard over six months ago Disposition of 10000 shares by Todd Berard of BioLife Solutions at 22.67 subject to Rule 16b-3 | ||
Todd Berard over six months ago Disposition of 10000 shares by Todd Berard of BioLife Solutions at 15.67 subject to Rule 16b-3 |
BioLife Solutions Management Efficiency
The company has return on total asset (ROA) of (0.0597) % which means that it has lost $0.0597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1504) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 306.7 M in 2024, whereas Intangible Assets are likely to drop slightly above 19.5 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| William Burke | Haemonetics | 52 | |
| Virginia Sanzone | ICU Medical | 49 | |
| Justin Noznesky | AtriCure | 46 | |
| Cameron Hicks | Teleflex Incorporated | 59 | |
| Don OCallaghan | West Pharmaceutical Services | N/A | |
| Michelle Basil | Haemonetics | 52 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Richard McHale | ResMed Inc | 54 | |
| David Montecalvo | West Pharmaceutical Services | 54 | |
| Gael Touya | AptarGroup | 54 | |
| James Darecca | Haemonetics | 50 | |
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Jake Newman | Teleflex Incorporated | N/A | |
| Bernard Birkett | West Pharmaceutical Services | 55 | |
| Chad Winters | West Pharmaceutical Services | 45 | |
| Bobby Ghoshal | ResMed Inc | 52 | |
| Silji Abraham | West Pharmaceutical Services | 52 | |
| Pascal Bamford | Akoya Biosciences | N/A | |
| Hedi Tlili | AptarGroup | 48 | |
| Randal Golden | The Cooper Companies, | 57 | |
| David Helsel | AngioDynamics | 60 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0597 |
BioLife Solutions Leadership Team
Elected by the shareholders, the BioLife Solutions' board of directors comprises two types of representatives: BioLife Solutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLife. The board's role is to monitor BioLife Solutions' management team and ensure that shareholders' interests are well served. BioLife Solutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLife Solutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aby Mathew, Chairman of Scientific Advisory Board, CTO and Sr. VP | ||
| Sarah JD, Chief Officer | ||
| Troy Wichterman, Chief Officer | ||
| Geraint Phillips, Senior Operations | ||
| Todd Berard, Vice President of Marketing | ||
| Karen Foster, Vice President - Operations | ||
| Troy CPA, Chief Officer | ||
| Sean Werner, Chief Officer | ||
| Marcus Schulz, Chief Officer | ||
| Michael Rice, CEO and President and Director | ||
| Roderick Greef, Interim CFO, Interim Secretary |
BioLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLife Solutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0597 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 1.28 B | ||||
| Shares Outstanding | 46.39 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 99.49 % | ||||
| Number Of Shares Shorted | 2.68 M | ||||
| Price To Earning | 173.59 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.